Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes

Sara Kazempour-Ardebili, Varunika L Lecamwasam, Thushara Dassanyake, Andrew H Frankel, Frederick W K Tam, Anne Dornhorst, Gary Frost, Jeremy J O Turner, Sara Kazempour-Ardebili, Varunika L Lecamwasam, Thushara Dassanyake, Andrew H Frankel, Frederick W K Tam, Anne Dornhorst, Gary Frost, Jeremy J O Turner

Abstract

Objective: Optimizing glycemic control in diabetic patients undergoing maintenance hemodialysis requires accurate assessment. We hypothesize that 1) 48-h continuous glucose monitoring (CGM) provides additional, clinically relevant, information to that provided by the A1C measurement and 2) glycemic profiles differ significantly between day on and day off dialysis.

Research design and methods: With the use of GlucoDay S, 48-h CGM was performed in 19 type 2 diabetic subjects undergoing hemodialysis to capture consecutive 24-h periods on and off dialysis. Energy intake was calculated using food diaries. A1C was assayed by a high-performance liquid chromatography method.

Results: CGM data were available for 17 subjects (13 male) with a mean (range) age of 61.5 years (42-79 years) and diabetes duration of 18.8 years (4-30 years). The 24-h CGM area under the glucose curve and 24-h mean glucose values were significantly higher during the day off dialysis than on dialysis (5,932.1 +/- 2,673.6 vs. 4,694 +/- 1,988.0 mmol x 3 min(-1) x l(-1), P = 0.022, and 12.6 +/- 5.6 vs. 9.8 +/- 3.8 mmol/l, P = 0.013, respectively), independent of energy intake. Asymptomatic hypoglycemia occurred in 4 subjects, 3 within 24 h of dialysis, and the glucose nadir in 14 subjects occurred within 24 h of dialysis.

Conclusions: Glucose values are significantly lower on dialysis days than on nondialysis days despite similar energy intake. The risk of asymptomatic hypoglycemia was highest within 24 h of dialysis. Physicians caring for patients undergoing hemodialysis need to be aware of this phenomenon and consider enhanced glycemic monitoring after a hemodialysis session. CGM provides glycemic information in addition to A1C, which is potentially relevant to clinical management.

Figures

Figure 1
Figure 1
CGM data for day on (day 1) and day off (day 2) dialysis, expressed as AUC glucose (A) and mean glucose (B) for each 24-h period. ▲—▲, data for individual subjects; ■, mean ± SD for each 24-h period. A: Mean ± SD area under the 3-min glucose curve for the whole study group was 5,932.1 ± 2,673.6 mmol · 3 min−1 · l−1 on the day off dialysis vs. 4,694 ± 1,988 mmol · 3 min−1 · l−1 on the day on dialysis (P = 0.022). B: Mean ± SD CGM glucose values for the whole group were 12.6 ± 5.6 mmol/l on the day off dialysis vs. 9.8 ± 3.8 mmol/l on the day on dialysis (P = 0.013).
Figure 2
Figure 2
Nocturnal CGM data for the 6-h period from midnight to 6:00 a.m. for day on (night 1) and day off (night 2) dialysis, expressed as AUC glucose (A) and mean glucose (B). ▲—▲, data for individual subjects; ■, mean ± SD for each 24-h period. A: Mean ± SD area under the 3-min glucose curve for the whole study group was 1,541 ± 834 mmol · 3 min−1 · l−1 for the night of the day off dialysis (night 2) vs. 1,137 ± 529 mmol · 3 min−1 · l−1 for the night of the day on dialysis (night 1) (P < 0.05). B: Mean ± SD CGM glucose values for the whole group were 12.9 ± 7.0 mmol/l on night 2 vs. 9.5 ± 4.4 mmol/l on night 1.

References

    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038– 2047
    1. United States Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States [article online], 2007. Available from . Accessed 12 September 2008
    1. Hakim RM, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21: 125– 137
    1. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12– S154
    1. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2002; 25: S28– S32
    1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643– 2653
    1. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545– 2559
    1. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560– 2572
    1. Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Fouque D, Laville M, Leverve XM: Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 2002; 62: 593– 601
    1. American Diabetes Association. Intense blood glucose control yields no significant effect on CVD reduction in VA Diabetes Trial [article online], 2008. Available from . Accessed 12 Sep- tember 2008
    1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977– 986
    1. NICE, National Institute of Health and Clinical Excellence. Clinical guidelines for the management of type 2 diabetes [article online], 2008. Available from . Accessed on 12 September 2008
    1. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care 2007; 30: S4– S41
    1. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275– 278
    1. Little RR, Tennill AL, Rohlfing C, Wiedmyere HM, Khanna R, Goel S, Agrawal A, Madsen R, Goldstein DE: Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem 2002; 48: 784– 786
    1. Nissenson AR, Fine RN: Dialysis Therapy. 3rd ed. Philadelphia, Hanley & Belfus, 2002
    1. Bry L, Chen PC, Sacks DB: Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47: 153– 163
    1. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G, Bistoni S, Calabrese G, Santeusanio F, Leonetti F, Ribaudo M, DiMario U, Annuzzi G, Genovese S, Ricardi G, Previti M, Cucinotta D, Giorgino F, Bellomo A, Giorgino R, Poscia A, Varalli M: Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 2002; 25: 347– 352
    1. Nelson M, Atkinson M, Meyer J. Nutritional Epidemiology Group UK. Food Portion Sizes: A Photographic Atlas. London, MAFF Publications, 1997
    1. Renal Association. Treatment of Adults and Children with Renal Failure: Standards and Audit Measures. 3rd ed. London, Royal College of Physicians of London and the Renal Association, 2002
    1. Takahashi A, Kubota T, Shibahara N, Terasaki J, Kagitani M, Ueda H, Inoue T, Katsuoka Y: The mechanism of hypoglycemia caused by hemodialysis. Clin Nephrol 2004; 62: 362– 368
    1. Williams ME, Lacson E, Jr, Teng M, Ofsthun N, Lazarus JM: Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503– 1509
    1. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, Shoji T, Nishizawa Y: Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496– 1500
    1. Lee KF, Szeto YT, Benzie IF: Glycohaemoglobin measurement: methodological differences in relation to interference by urea. Acta Diabetol 2002; 39: 35– 39
    1. Schnedl WJ, Lahousen T, Wallner SJ, Krause R, Lipp RW: Silent hemoglobin variants and determination of HbA1c with the high-resolution program of the HPLC HA-8160 hemoglobin analyzer. Clin Biochem 2005; 38: 88– 91
    1. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297– 307
    1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. A1c-Derived Average Glucose Study Group: Translating the A1c assay into estimated average glucose values. Diabetes Care 2008; 31: 1473– 1478

Source: PubMed

3
Abonnieren